key: cord-0886785-zkfbbpjh authors: Chen, Chong-xiang; Hu, Fang; Wei, Jin; Yuan, Le-tao; Wen, Tian-meng; Gale, Robert Peter; Liang, Yang title: Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) date: 2021-05-17 journal: Leukemia DOI: 10.1038/s41375-021-01264-8 sha: 2b11c720195c2aed6e78f15a492dbcb94b81f407 doc_id: 886785 cord_uid: zkfbbpjh We performed a meta-analysis to determine safety and efficacy of tocilizumab in persons with coronavirus disease-2019 (COVID-19). We searched PubMed, Web of Science and Medline using Boolean operators for studies with the terms coronavirus OR COVID-19 OR 2019-nCoV OR SARS-CoV-2 AND tocilizumab. Review Manager 5.4 was used to analyze data and the modified Newcastle–Ottawa and Jadad scales for quality assessment. We identified 32 studies in 11,487 subjects including three randomized trials and 29 cohort studies with a comparator cohort, including historical controls (N = 5), a matched cohort (N = 12), or concurrent controls (N = 12). Overall, tocilizumab decreased risk of death (Relative Risk [RR] = 0.74; 95% confidence interval [CI], 0.59, 0.93; P = 0.008; I(2) = 80%) but not of surrogate endpoints including ICU admission (RR = 1.40 [0.64,3.06]; P = 0.4; I(2) = 88%), invasive mechanical ventilation (RR = 0.83 [0.57,1.22]; P = 0.34; I(2) = 65%) or secondary infections (RR = 1.30 [0.97,1.74]; P = 0.08; I(2) = 65%) and increased interval of hospitalization of subjects discharged alive(mean difference [MD] = 2 days [<1, 4 days]; P = 0.006; I(2) = 0). RRs of death in studies with historical controls (RR = 0.28 [0.16,0.49; P < 0.001]; I(2) = 62%) or a matched cohort (RR = 0.68 [0.53, 0.87]; P = 0.002; I(2) = 42%) were decreased. In contrast, RRs of death in studies with a concurrent control (RR = 1.10 [0.77, 1.56]; P = 0.60; I(2) = 85%) or randomized (RR = 1.18 [0.57,2.44]; P = 0.66; I(2) = 0) were not decreased. A reduced risk of death was not confirmed in our analyses which questions safety and efficacy of tocilizumab in persons with COVID-19. Infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-2019 (COVID- 19) , an important pathogenetic component of which is cytokine release syndrome (CRS). CRS is mediated, at least in part, by interleukin-6 (IL-6). Tocilizumab, a humanized monoclonal antibody, selectively targets the interleukin-6 receptor (IL-6r) [1, 2] and is reported safe and effective in other settings such as after chimeric antigen receptor (CAR)-Tcell therapy, rheumatoid arthritis, and giant cell arteritis [3, 4] . Data from 11 uncontrolled studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and most prior meta-analyses [17] [18] [19] [20] [21] [22] [23] [24] claim tocilizumab is safe and effective in persons with COVID-19. However, data from three recent randomized controlled trials (RCTs) question this conclusion [25] [26] [27] . We conducted a systematic review and meta-analysis of 32 studies of safety and efficacy of tocilizumab in persons with COVID-19 which had a comparator cohort. Overall, we found tocilizumab decreased risk of death but not rates of intensive care unit(ICU) admission, invasive mechanical ventilation, secondary infections, and increased interval of hospitalization in persons discharged alive. However, a reduced risk of death was not confirmed in our analyses of studies with concurrent controls nor randomized trials. These data question safety and efficacy of tocilizumab in persons with COVID-19. PubMed, Web of Science and Medline were searched using Boolean operators for studies with the terms coronavirus OR COVID-19 OR 2019-nCoV OR SARS-CoV-2 AND tocilizumab. Start and stop dates were 2020/1/1 and 2020/ 10/27. Two investigators independently reviewed abstracts of identified citations and selected articles for full review. Discordances were resolved by a third reviewer. Results were also manually searched and reviewed. We found 1492 articles excluding 914 duplicates. After further review we focused on 32 studies, 29 non-randomized comparator studies, and three RCTs [1, 2, . A flow diagram of the search strategy and article selection is displayed in Fig. 1 . Review Manager 5.4 was used to analyze data and the modified Newcastle-Ottawa score (NOS) and Jadad scale for quality assessment. Inclusion criteria included English language reports of clinical trials and observational studies with a comparator cohort and with outcomes reporting, but not limited to, survival. Reviews and case reports were excluded as were studies with a NOS < 6. For each selected article we extracted (1) first author, (2) publication year, (3) country, (4) study-design, (5) number of subjects, (6) comparator cohort, (7) baseline subject clinical and laboratory co-variates, (8) details of tocilizumab use, (9) concurrent interventions, and (10) outcomes, including: (1) survival, (2) rates of ICU admission, (3) invasive mechanical ventilation, (4) secondary infection, and (5) interval of hospitalization. The study used anonymized, published data with no requirement for Ethics Committee approval. (Table 1; Supplement Table 1 ) Risk of bias was assessed using the Jadad scale in four domains: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants, and (4) complete reporting of withdrawals and dropouts [53] . Methodological quality of comparator studies was assessed using the modified Newcastle-Ottawa scale (NOS) [54, 55] consisting of three domains: (1) subject selection, (2) comparability of the study groups, and (3) outcomes assessment. A score of 0-9 was allocated to each relevant study. Observational studies with a NOS score <6 (N = 1) were excluded [56] . We pooled data and utilized Relative Risks (RRs) and Confidence Intervals (CIs) to describe dichotomous outcomes, including risk of death, ICU admission, invasive mechanical ventilation, secondary infection . We used mean difference (MD) and CIs for continuous outcomes including interval of hospitalization. We grouped the cohort studies into unmatched historical controls and concurrent controls, matched and unmatched or subgroup analyses. A fixedeffects model was used when I 2 ≤ 50% and the Cochran Q statistic P > 0.1 and a random-effects model when I 2 > 50% and Q statistic P ≤ 0.1. Funnel plots were used to screen for potential publication bias. Statistical analyses were carried out with Review Manager 5.4 (Cochrane Collaboration) We included 11,487 subjects from 29 studies (NOS scores 6-9) with a comparator cohort including historical controls (N = 5) [1, 30, 32, 35, 43] , a matched cohort (N = 12) [2, 28, 29, 33, 40, 44-47, 49, 50, 57] or concurrent controls (N = 12) [31, 34, 36-39, 41, 42, 48, 51, 52, 58] and three randomized controlled trials (Jadad scales 4-5). We excluded some studies because they were uncontrolled (N = 11) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and/or different study-entry severities of COVID-19 between treated subjects and controls (N = 1) [59] . Two studies reported only a composite endpoint (ICU admission, use of mechanical ventilation or death) [57, 58] . These were included in the systemic review but not used to estimate RRs for specific endpoints. To test the efficacy of tocilizumab on rate of ICU admission we included seven studies [25-27, 31, 41, 42, 45] RR relative risk, NA not available. Chong-xiang Chen et al. Potential for publication bias is shown in Fig. 6 . We found potential publication bias in studies of death in subjects receiving or not receiving tocilizumab with some studies falling outside the 95% CI of the funnel plot. There was publication bias in studies included in the meta-analysis. Increased concentrations of inflammatory cytokines (IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor-a (TNF-a) are reported in persons with COVID-19 [60, 61] . IL-6 is produced by diverse immune cells and implicated in development of acute respiratory distress syndrome (ARDS) and CRS Chong-xiang Chen et al. [62, 63] . Some data suggest increased IL-6 concentrations correlate with risk of death [61, 64] . Several metaanalyses claim tocilizumab is safe and effective in COVID-19 [17, 21, 23, 24] . Most studies we include gave tocilizumab to subjects with evidence of inflammation including a CRP concentration >100 mg/L, a ferritin concentration >900 ng/ml and/or a D-dimer concentration >1500 ug/L [1] . Evaluating all 32 studies we found tocilizumab reduced risk of death but not several surrogate endpoints, including ICU admission, invasive mechanical ventilation, and secondary infections. Hospitalization interval was significantly increased. However, in our analysis of RCTs and studies with a concurrent control cohort we could not confirm a decreased risk of death. This conclusion differs from most prior meta-analyses [17] [18] [19] [20] [21] [22] [23] [24] which failed to analyze outcomes by study-design (Table 3) . A recent meta-analysis concluded an association between tocilizumab and lower mortality by low certainty evidence from cohort studies [22] . Our data contradict this assumption. Two recent analyses which included only studies with a comparator cohort support our conclusion [65, 66] . Also, Mao and colleagues reported use of tocilizumab did not decrease risk of death possibly because of an increased risk of secondary bacterial infections [67] . There are important limitations to our study. Firstly, subjects were heterogeneous in COVID-19 severity although most had severe to critical COVID-19. Secondly, many studies were observational and lacked an appropriate control cohort. We tried to overcome potential biases in these studies by analyzing outcomes by study-type. RR relative risk, OR odds ratios, RD risk differences, RCTs randomized controlled trials. In conclusion, tocilizumab decreased risk of death but not rates of surrogate endpoints including ICU admission, invasive mechanical ventilation, secondary infections and did significantly alter interval of hospitalization. A reduced risk of death was not confirmed in our meta-analysis of randomized trials or studies with a concurrent control cohort. These data question safety and efficacy of tocilizumab in persons with COVID-19. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: a retrospective case-control survival analysis of 128 patients A panoramic review of IL-6: structure, pathophysiological roles and inhibitors FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome Promising effects of tocilizumab in COVID-19: a noncontrolled, prospective clinical trial Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study Temporal clinical and laboratory response to interleukin-6 receptor blockade with tocilizumab in 89 hospitalized patients with COVID-19 pneumonia Tocilizumab treatment in COVID-19: a single center experience Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective openlabel uncontrolled multicenter trial Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: an observational cohort study Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: a retrospective cohort study. Indian j of med microbiol Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. Clin and transl sci Online ahead of print Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia Effective treatment of severe COVID-19 patients with tocilizumab Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis. Front in med Use of Tocilizumab in COVID-19: a systematic review and metaanalysis of current evidence Tocilizumab for severe COVID-19: a systematic review and metaanalysis. Int j of antimicrob agents Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis Efficacy of tocilizumab treatment in severely ill COVID-19 patients Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies Efficacy of Tocilizumab in patients hospitalized with Covid-19. The N Engl j of med Effect of Tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 Pneumonia: a randomized clinical trial Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial Observational study on off-label use of tocilizumab in patients with severe COVID-19 Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study Tocilizumab in patients with severe COVID-19: a retrospective cohort study Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: a retrospective observational study Association between early treatment with Tocilizumab and mortality among critically ill patients with COVID-19 Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation Tocilizumab use in COVID-19-associated pneumonia Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann of the rheum dis Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study Effect of Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case-control cohort study Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis Tocilizumab for treatment of mechanically Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) ventilated patients with COVID-19 Efficacy and safety of tocilizumab in COVID-19 patients Assessing the quality of reports of randomized clinical trials: is blinding necessary? Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care COVID-19: consider cytokine storm syndromes and immunosuppression Clinical features of patients infected with 2019 novel coronavirus in Wuhan Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients Tocilizumab in hospitalized patients with COVID-19: clinical outcomes, inflammatory marker kinetics, and safety Tocilizumab for Severe Worsening COVID-19 Pneumonia: a propensity score analysis Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions? Proc of the Natl Acad of Sci These authors contributed equally: Chong-xiang Chen, Fang Hu, Jin Wei